The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
This transaction fundamentally strengthens Scinai's CDMO platform
Iberdomide has the potential to be the first approved CELMoD agent
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
Subscribe To Our Newsletter & Stay Updated
